Compare CGC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGC | EYPT |
|---|---|---|
| Founded | N/A | 1987 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.0M | 273.3M |
| IPO Year | 2023 | 2005 |
| Metric | CGC | EYPT |
|---|---|---|
| Price | $0.43 | $0.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $8.31 |
| AVG Volume (30 Days) | 2.5M | ★ 5.8M |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,759,000.00 | $7,539,000.00 |
| Revenue This Year | $18.91 | N/A |
| Revenue Next Year | $6.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.26 |
| 52 Week High | $2.38 | $19.11 |
| Indicator | CGC | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 19.41 | 16.61 |
| Support Level | N/A | N/A |
| Resistance Level | $1.08 | $3.57 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 0.54 | 2.11 |
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.